In pancreatic cancer, inhibition of the CXCL12/CXCR4 axis arrested cell growth and abrogated gemcitabine resistance [125] as well as reduced tumor growth in animal models by blocking CXCR4-dependent mast cell migration [126]. Here, CXCL12 is linked to neoplasm.